firsocostat + cilofexor + fenofibrate

This is a **combination therapy** of three small molecule drugs: firsocostat (an acetyl-CoA carboxylase inhibitor), cilofexor (a farnesoid X receptor agonist), and fenofibrate (a peroxisome proliferator-activated receptor alpha agonist)[2][4][5]. This regimen is primarily investigated for the treatment of nonalcoholic steatohepatitis (NASH) with advanced fibrosis and cirrhosis, aiming to reduce liver fat, improve liver biochemistry, mitigate increases in triglycerides, and potentially regress fibrosis. Firsocostat and cilofexor target hepatic fatty acid metabolism and bile acid signaling, respectively, whereas fenofibrate controls hypertriglyceridemia induced by firsocostat/cilofexor[2].

Other names

firsocostatcilofexorfenofibrate